Singh 1995.
| Methods | Randomised clinical trial | |
| Participants | Country: USA Period of recruitment: not stated Number randomised: 60 Postrandomisation dropouts: 0 (0%) Revised sample size: 60 Mean age (years): 45 Females: not stated Presence of other features of decompensation (hepatorenal syndrome, hepatic encephalopathy, or variceal bleeding): not stated Ascites with low protein: not stated Primary prophylaxis: 47 (78.3%) Alcohol‐related cirrhosis: 24 (40.0%) Viral‐related cirrhosis: 31 (51.7%) Autoimmune disease‐related cirrhosis (e.g. PSC, PBC, AIH): not stated Other causes for cirrhosis: 5 (8.3%) Treated for ascites in addition to antibiotics (e.g. albumin or diuretics): not stated Exclusion criteria:
|
|
| Interventions | Participants randomly assigned to 2 groups. Group 1: sulfamethoxazole + trimethoprim (n = 30) Further details: sulfamethoxazole 160 mg + trimethoprim 800 mg daily (duration not stated, but probably until follow‐up) Group 2: no active intervention (n = 30) Further details: no treatment |
|
| Outcomes | Outcomes reported: all‐cause mortality; number of any adverse events per participant; proportion with spontaneous bacterial peritonitis (as per definition). Follow‐up (months): 3 |
|
| Notes | Attempted to contact authors in November 2018, but received no replies. | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Comment: information not available |
| Allocation concealment (selection bias) | Unclear risk | Comment: information not available |
| Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Comment: information not available |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Comment: information not available |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Comment: no postrandomisation dropouts |
| Selective reporting (reporting bias) | Low risk | Comment: protocol not available, but authors reported mortality and adverse events adequately. |
| Other bias | Low risk | Comment: no other bias noted |